Long‐term trends in hepatitis C prevalence, treatment uptake and liver‐related events in the Swiss HIV Cohort Study DOI Creative Commons
Lukas Baumann, Dominique L. Braun, Matthias Cavassini

et al.

Liver International, Journal Year: 2023, Volume and Issue: 44(1), P. 169 - 179

Published: Oct. 18, 2023

Abstract Background and Aims Treatment for chronic hepatitis C virus (HCV) infections changed dramatically in the last decade. We assessed changes prevalence of replicating HCV infection, treatment uptake liver‐related morbidity mortality persons with HIV (PWH) Swiss cohort study. Methods included all participants between 2002 2021. yearly overall mortality, as well incidence events at least one documented positive HCV‐RNA. Results Of 14 652 under follow‐up, 2294 had HCV‐RNA measurement. those, 1316 (57%) ever received an treatment. increased from 8.1% to a maximum 32.6% 2016. Overall, infection declined 16.5% 2004 1.3% 63.2% 7.1% who inject drugs, 4.1% 0.6% men have sex men. Among 3.3 per 100 patient‐years (PY) 1.1 PY, decreased 1.4/100 PY 0.2/100 PY. Conclusions The introduction DAA therapy was associated more than 10‐fold reduction PWH, approaching estimates general population. Overall substantially living C.

Language: Английский

Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection DOI Open Access
Debika Bhattacharya,

Andrew Aronsohn,

Jennifer C. Price

et al.

Clinical Infectious Diseases, Journal Year: 2023, Volume and Issue: unknown

Published: May 25, 2023

The Infectious Diseases Society of America and the American Association for Study Liver have collaboratively developed evidence-based guidance regarding diagnosis, management, treatment hepatitis C virus (HCV) infection since 2013. A panel clinicians investigators with extensive infectious diseases or hepatology expertise specific to HCV periodically review evidence from field update existing recommendations introduce new as warrants. This focuses on changes previous 2020 published update, including ongoing emphasis recommended universal screening; management incomplete adherence; expanded eligibility simplified chronic in adults minimal monitoring; updated retreatment children young 3 years old; transplantation setting; screening, treatment, unique key populations.

Language: Английский

Citations

135
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology DOI
Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(12), P. 797 - 809

Published: Aug. 3, 2023

Language: Английский

Citations

86
A National Hepatitis C Elimination Program in the United States DOI Open Access

Rachael Fleurence,

Francis S. Collins

JAMA, Journal Year: 2023, Volume and Issue: 329(15), P. 1251 - 1251

Published: March 9, 2023

This Viewpoint introduces a proposed 5-year program from the Biden-Harris administration that would use direct-acting antivirals to eliminate hepatitis C in United States.

Language: Английский

Citations

72
The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction–associated steatotic liver disease and alcohol-associated liver disease DOI Creative Commons
Zobair M. Younossi, Maria Stepanova, Reem Q. Al Shabeeb

et al.

Hepatology Communications, Journal Year: 2023, Volume and Issue: 8(1)

Published: Dec. 21, 2023

The high prevalence of obesity in the United States drives burden NASH, recently renamed as metabolic dysfunction-associated steatohepatitis (MASH). We assessed most recent trends liver transplantation States.

Language: Английский

Citations

53
Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019 DOI Open Access
Farhad Islami, Emily C. Marlow, Blake Thomson

et al.

CA A Cancer Journal for Clinicians, Journal Year: 2024, Volume and Issue: 74(5), P. 405 - 432

Published: July 11, 2024

In 2018, the authors reported estimates of number and proportion cancers attributable to potentially modifiable risk factors in 2014 United States. These data are useful for advocating informing cancer prevention control. Herein, based on up-to-date relative occurrence data, estimated invasive cases (excluding nonmelanoma skin cancers) deaths, overall 30 types among adults who were aged years older 2019 States, that factors. included cigarette smoking; second-hand smoke; excess body weight; alcohol consumption; consumption red processed meat; low fruits vegetables, dietary fiber, calcium; physical inactivity; ultraviolet radiation; seven carcinogenic infections. Numbers deaths obtained from sources with complete national coverage, factor prevalence nationally representative surveys, associated risks published large-scale pooled or meta-analyses. 2019, an 40.0% (713,340 1,781,649) all incident 44.0% (262,120 595,737) States evaluated Cigarette smoking was leading contributing (19.3% 28.5%, respectively), followed by weight (7.6% 7.3%, (5.4% 4.1%, respectively). For 19 types, more than one half considered this study. Lung had highest (201,660) (122,740) factors, female breast (83,840 cases), melanoma (82,710), colorectal (78,440) (25,800 deaths), liver (14,720), esophageal (13,600) deaths. Large numbers underscoring potential substantially reduce burden through broad equitable implementation preventive initiatives.

Language: Английский

Citations

45
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions DOI
Lung‐Yi Mak, Ken Liu, Sakkarin Chirapongsathorn

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 21(12), P. 834 - 851

Published: Aug. 15, 2024

Language: Английский

Citations

29
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma DOI
Daniel Q. Huang, Joseph Hoang, Rubayet Kamal

et al.

Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 42(7), P. 790 - 799

Published: Jan. 4, 2024

There are limited data on antiviral treatment

Language: Английский

Citations

18
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection DOI Open Access
Yu‐Ping Chang,

Ji‐Yuh Lee,

Chi‐Yi Chen

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 21, 2025

ABSTRACT Background Data regarding the risk of incident type 2 diabetes (T2D) and prediabetes among patients with hepatitis C virus (HCV) achieving direct‐acting antivirals (DAAs)‐induced sustained virologic response (SVR 12 ) remains limited. Methods A total 1079 patients, including 589 normoglycemia 490 prediabetes, who underwent biannual fasting glucose glycosylated haemoglobin (HbA1c) assessment for a median post‐SVR follow‐up 5.5 years, were enrolled. We reported crude (cIRs) age‐standardised incidence rates (ASIRs) T2D prediabetes. Factors associated assessed using Cox proportional hazards models. Results The cIRs 1.18 8.99 per 100 person‐years (PYFU), respectively. Additionally, ASIRs 1.09 (95% CI: 0.76–1.53) 8.47 7.23–9.90) PYFU. Prediabetes (adjusted hazard ratio [aHR]: 4.71; 95% confidence interval (CI): 2.55–8.70, p < 0.001), body mass index (BMI) kg/m increase (aHR: 1.17; 1.09–1.26, 0.001) liver stiffness measurement (LSM) kPa 1.05; 1.02–1.09, = higher T2D. Age year 1.02; 1.01–1.03, was Conclusion remain substantial after HCV eradication. Lifestyle modification, drug therapy regular monitoring glycemic status are crucial at developing following clearance.

Language: Английский

Citations

2
Global treatment rate and barriers to direct‐acting antiviral therapy: A systematic review and meta‐analysis of 146 studies and 1 760 352 hepatitis C virus patients DOI
Vy H. Nguyen, Daniel Q. Huang, Michael H. Le

et al.

Liver International, Journal Year: 2023, Volume and Issue: 43(6), P. 1195 - 1203

Published: Feb. 24, 2023

Global data on the treatment rate with direct-acting antivirals (DAAs) for chronic hepatitis C (CHC) are sparse. We aimed to evaluate CHC and barriers in DAA era.We searched PubMed, EMBASE Cochrane from inception 5 August 2021, relevant articles. Patients treated DAAs without interferon (IFN) therapy were categorized as IFN-free DAAs. receiving IFN or unclear status DAA/IFN.We identified analysed 146 studies (1 760 352 patients). DAA/IFN was 16.0% (95% CI: 9.9-23.3, 49 studies, 886 535 52.3% 46.2-58.4, 123 1 276 754 patients): 45.4% North America, 64.2% South America study), 90.4% Africa (most Egypt), 54.4% Europe, 60.7% Australia 60.5% Asia, (p < .0001); 49% B co-infection 32.3% hepatocellular carcinoma (HCC). Treatment not a priority 22.8% of patients Europe 16.7% Australia, compared only 4.8% 2.1% Asia .0001). Poor adherence clinical follow-up cause no 74.7% 37.0% 7.9% 14.3% .0001).Though marked improvement IFN/DAA, remains suboptimal (52.3% overall, HCC Non-adherence lack disease awareness barriers.

Language: Английский

Citations

11
Medicaid Expansion and Restriction Policies for Hepatitis C Treatment DOI Creative Commons
Nathan W. Furukawa, Susan Z. Ingber, Hasan Symum

et al.

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(7), P. e2422406 - e2422406

Published: July 16, 2024

Importance Hepatitis C can be cured with direct-acting antivirals (DAAs), but Medicaid programs have implemented fibrosis, sobriety, and prescriber restrictions to control costs. Although are easing, understanding their association hepatitis treatment rates is crucial inform policies that increase access lifesaving treatment. Objective To estimate the of jurisdictional (50 states Washington, DC) DAA expansion number recipients filled prescriptions for DAAs. Design, Setting, Participants This cross-sectional study used publicly available documents claims data from January 1, 2014, December 31, 2021, compare unique treated DAAs in each jurisdiction year status categories restrictions. all 50 DC, during period were included. Multilevel Poisson regression was between restrictive on prescription fills. Data analyzed initially August 15 November 15, 2023, subsequently April May 9, 2024. Exposures Jurisdictional Main Outcomes Measures Number people per 100 000 year. Results A total 381 373 (57.3% aged 45-64 years; 58.7% men; 15.2% non-Hispanic Black 52.2% White). nonexpansion jurisdictions had fewer than (38.6 vs 86.6; adjusted relative risk [ARR], 0.56 [95% CI, 0.52-0.61]). Jurisdictions F3 F4 (34.0 year; ARR, 0.39 0.37-0.66]) or F1 F2 fibrosis (61.9 0.62 0.59-0.66]) lower without (94.8 year). Compared no sobriety (113.5 year), 6 12 months (38.3 0.65 0.61-0.71]) screening counseling requirements (84.7 0.87 0.83-0.92]) associated reduced rates, while 1 5 not statistically significantly different. (97.8 specialist consult increased (66.2 1.05 1.00-1.10]), required significant. Conclusions Relevance In this study, status, a reduction who C. Removing might facilitate more diagnosed

Language: Английский

Citations

4